Related Experiment Videos
Overview of MTA in the treatment of non-small cell lung cancer
1Department of Pulmonology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands.
Abstract:
While advanced non-small cell lung cancer is a malignancy which remains largely refractory to chemotherapy, the 1990s have seen gains in both the number of agents available as well as the frequency of use of these agents in the treatment of non-small cell lung cancer. This report reviews several studies of MTA (multitargeted antifolate, LY23 1514), a novel antifolate, as first- and second-line treatment. MTA has been tested in advanced non-small cell lung cancer in a variety of patient populations, including those who have received no prior chemotherapy, those who have relapsed following prior platinum-containing therapy, and those who have relapsed following prior chemotherapy which did not contain platinum. In both groups MTA was found to be active, its activity in chemonaive patients was comparable (14%-23%) to currently used new drugs like taxanes and gemcitabine. Additionally, MTA has been studied in combination with cisplatin in patients who are chemotherapy-naive, with a response rate (42%) comparable to other modern combination regimens. Preliminary data appear promising and will be discussed.
Insights
Multitargeted antifolate (MTA) shows promise in treating advanced non-small cell lung cancer. MTA demonstrated comparable activity to current therapies in both first- and second-line settings.
Area of Science:
- Oncology
- Pharmacology
Background:
- Advanced non-small cell lung cancer (NSCLC) is often resistant to chemotherapy.
- The 1990s saw an increase in available chemotherapy agents for NSCLC.
Purpose of the Study:
- To review studies on multitargeted antifolate (MTA, LY23 1514) for advanced NSCLC.
- To evaluate MTA as both first- and second-line treatment.
Main Methods:
- Review of clinical studies involving MTA in advanced NSCLC patients.
- Analysis of patient populations including chemotherapy-naive and previously treated individuals.
- Assessment of MTA efficacy as monotherapy and in combination with cisplatin.
Main Results:
- MTA demonstrated activity in both chemotherapy-naive (14%-23% response rate) and previously treated NSCLC patients.
- MTA's efficacy in naive patients was comparable to taxanes and gemcitabine.
- Combination therapy with MTA and cisplatin yielded a 42% response rate in naive patients.
Conclusions:
- MTA shows promising activity as a novel antifolate in advanced NSCLC.
- MTA is a viable option for both first- and second-line treatment of NSCLC.
- Further investigation into MTA, particularly in combination regimens, is warranted.